SCHEMBL30424922

SCHEMBL30424922

OC(=Nc1ccccc1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 2/20 0.48
HTR3B O95264 2/20 0.48
HTR3A P46098 2/20 0.48
HTR3D Q70Z44 2/20 0.48
HTR3C Q8WXA8 2/20 0.48
SLC22A2 O15244 1/20 0.48
SLC22A1 O15245 1/20 0.48
SLC22A3 O75751 1/20 0.48
PLAU P00749 1/20 0.48
NOS1 P29475 4/20 0.46
NOS3 P29474 3/20 0.46
MAPT P10636 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31513660 1.00 HTR3E (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL11568501 0.82 HTR3E (0.50) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL28674580 0.76 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16374609 0.76 NOS1 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1743759 0.76 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL5140496 0.76 NOS1 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL398432 0.76 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL398431 0.76 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL9908807 0.73 NOS1 (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL12886316 0.72 CES2 (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103449-A1 PRODRUG ATHELIAPYRROLIDINE COMPOUND AND METHODS OF USE UNIV FLORIDA (US) 2026-04-16 US disclosed
WO-2024220385-A1 PRODRUG ATHELIAPYRROLIDINE COMPOUND AND METHODS OF USE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-10-24 WO disclosed
EP-4426710-A1 SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS Université de Montréal (CA) 2024-09-11 EP disclosed
US-20240218010-A1 Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof PROGEN PG500 SERIES PTY LTD (AU) 2024-07-04 US disclosed
WO-2023070223-A1 SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS Université de Montréal (CA) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218010-A1 Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof OSTC, FUT5, NPY5R HTR3E 630/4885HTR3B 751/4885HTR3A 408/4885
US-20260103449-A1 PRODRUG ATHELIAPYRROLIDINE COMPOUND AND METHODS OF USE ADORA2A, HTR2A, HTR1D HTR3E 82/4885HTR3B 22/4885HTR3A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.